A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (NCT07069712)
A Master Protocol of an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)
🩺 Plain-English Summary (8th-Grade Level)
GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease.
Who can join: Review the eligibility criteria below.
Location: Research Site — Newark, Delaware
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (70 Sites)
Showing the first 25 of 70 sites.
- Research Site — Newark, Delaware
- Research Site — Washington D.C., District of Columbia
- Research Site — Fairway, Kansas
- Research Site — North Shores, Michigan
- Research Site — New York, New York
- Research Site — New York, New York
- Research Site — Pittsburgh, Pennsylvania
- Research Site — Toronto, Ontario
- Research Site — Montreal, Quebec
- Research Site — Montreal, Quebec
- Research Site — Beijing,
- Research Site — Changchun,
- Research Site — Changzhi,
- Research Site — Chengdu,
- Research Site — Chengdu,
- Research Site — Fuzhou,
- Research Site — Hangzhou,
- Research Site — Hangzhou,
- Research Site — Kunming,
- Research Site — Qingdao,
- Research Site — Shanghai,
- Research Site — Shijiazhuang,
- Research Site — Tbilisi,
- Research Site — Tbilisi,
- Research Site — Tbilisi,
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastroesophageal Adenocarcinoma
- Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) — Tampa, Florida
- RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial — Montreal,
- AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas — Los Angeles, California
- Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) — Orange, California
- Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma — Calgary, Alberta
Explore by condition: All Gastroesophageal Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.